Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 16/20 | 0.72 |
| ▸ | DRD1 | P21728 | 8/20 | 0.72 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.72 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.72 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.72 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.72 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.72 |
| ▸ | DRD4 | P21917 | 3/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.72 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.72 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.72 |
| ▸ | DRD3 | P35462 | 2/20 | 0.72 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.72 |
| ▸ | HTR2A | P28223 | 2/20 | 0.72 |
| ▸ | HTR2C | P28335 | 2/20 | 0.72 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.72 |
| ▸ | HRH1 | P35367 | 2/20 | 0.72 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9014028 | 1.00 | DRD2 (0.72) | DRD2DRD1CHRM1CHRM2CHRM4 | |
| SCHEMBL29898495 | 1.00 | DRD2 (0.72) | DRD2DRD1CHRM1CHRM2CHRM4 | |
| Hydrochloric Acid SCHEMBL30464869 | 0.99 | DRD2 (0.71) | DRD2DRD1CHRM1CHRM2CHRM4 | |
| Iodide SCHEMBL18639888 | 0.90 | DRD2 (0.73) | DRD2DRD1CHRM1CHRM2CHRM4 | |
| SCHEMBL18257470 | 0.89 | DRD2 (0.72) | DRD2DRD1CHRM1CHRM2CHRM4 | |
| SCHEMBL20887469 | 0.87 | DRD2 (0.88) | DRD2DRD1CHRM1CHRM2CHRM4 | |
| SCHEMBL3411429 | 0.85 | DRD2 (0.78) | DRD2DRD1CHRM1CHRM2CHRM4 | |
| Clozapine SCHEMBL8397 | 0.84 | DRD2 (1.00) | DRD2DRD1CHRM1CHRM2CHRM4 | |
| Clozapine SCHEMBL5501558 | 0.84 | DRD2 (1.00) | DRD2DRD1CHRM1CHRM2CHRM4 | |
| Clozapine SCHEMBL20876213 | 0.84 | DRD2 (1.00) | DRD2DRD1CHRM1CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 265 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3703716-B1 | EXPRESSION OF NEUROPEPTIDES | CALIFORNIA INST OF TECHN (US) | 2026-03-25 | — | — | EP | claimed |
| US-20260048145-A1 | COMPOSITIONS AND METHODS FOR TREATING DRUG ADDICTION | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2026-02-19 | — | — | US | claimed |
| EP-3507371-B1 | COMPOSITIONS FOR TREATING DISEASES AND DISORDERS OF THE NERVOUS SYSTEM | UNIV RUTGERS (US) | 2026-01-28 | — | — | EP | claimed |
| US-20250360171-A1 | CHEMOGENETICALLY GATED ION CHANNELS AND USE THEREOF | TECHNION RES & DEV FOUNDATION (IL) | 2025-11-27 | — | — | US | claimed |
| CN-120082519-A | Hybridoma cell strain secreting clozapine and metabolite monoclonal antibody thereof | 江南大学 | 2025-06-03 | — | — | CN | claimed |
| CN-120064523-A | Method for measuring 6 genotoxic impurities in rui Lu Geli by high performance liquid chromatography-mass spectrometry | 瑞阳制药股份有限公司 | 2025-05-30 | — | — | CN | claimed |
| US-20240417568-A1 | ADHESION PROMOTER FOR COMPOSITES AND METHODS THEREOF | THE BOEING COMPANY (US) | 2024-12-19 | — | — | US | claimed |
| EP-4477720-A1 | ADHESION PROMOTER FOR COMPOSITES AND METHODS THEREOF | The Boeing Company (US) | 2024-12-18 | — | — | EP | claimed |
| WO-2024248583-A1 | COMPOSITION FOR MIMICKING ACUPUNCTURE TREATMENT | 한국과학기술연구원 | 2024-12-05 | — | — | WO | claimed |
| EP-4448562-A2 | REGULATION OF IMMUNE RESPONSES THROUGH SELECTIVE NEURAL ACTIVATION | The Trustees of Columbia University in the City of New York (US) | 2024-10-23 | — | — | EP | claimed |
| WO-2024036257-A1 | COMPOSITIONS AND METHODS FOR TREATING DRUG ADDICTION | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2024-02-15 | — | — | WO | claimed |
| WO-2024004500-A1 | UTILIZATION OF A HIBERNATION-LIKE STATE IN NEUROLOGICAL DISEASES | OKINAWA INSTITUTE OF SCIENCE AND TECHNOLOGY SCHOOL CORPORATION (JP) | 2024-01-04 | — | — | WO | claimed |
| US-20230293770-A1 | USE OF PERFUSION DECELLULARIZED LIVER FOR ISLET CELL RECELLULARIZATION | MIROMATRIX MEDICAL INC. | 2023-09-21 | — | — | US | claimed |
| EP-3426307-B1 | USING DREADD FOR NEURONAL MODULATION IN TREATING NEURONAL DISEASES | ASSAF FADI (IL) | 2023-09-06 | — | — | EP | claimed |
| WO-2023114892-A2 | REGULATION OF IMMUNE RESPONSES THROUGH SELECTIVE NEURAL ACTIVATION | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-06-22 | — | — | WO | claimed |
| CN-114668765-B | Application of clozapine N-oxide in preparation of medicine for preventing and treating nitrogen anesthesia | 南通大学 | 2023-06-02 | — | — | CN | claimed |
| US-20220347321-A1 | EXPRESSION OF NEUROPEPTIDES | CALIFORNIA INST OF TECHN (US) | 2022-11-03 | — | — | US | claimed |
| US-11452797-B2 | Use of perfusion decellularized liver for islet cell recellularization | MIROMATRIX MEDICAL INC. (US) | 2022-09-27 | — | — | US | claimed |
| US-11400168-B2 | Methods and systems for noninvasive control of brain cells and related vectors and compositions | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2022-08-02 | — | — | US | claimed |
| US-11376337-B2 | Expression of neuropeptides | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2022-07-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260048145-A1 | COMPOSITIONS AND METHODS FOR TREATING DRUG ADDICTION | OPRK1, OPRL1, OPRD1 | DRD2 4/4885DRD1 9/4885CHRM1 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.